280 likes | 680 Views
Coagulation Disorders. FACTOR VIII DEFICIENCY HEMOPHILIA A. Factor VIII: Regulates the activation of factor X by proteases. Synthesized in liver, complexed to vWF. On the X chromosome. HEMOPHILIA A. Female carriers have sufficient factor VIII.
E N D
Coagulation Disorders Coagulation Disorders
FACTOR VIII DEFICIENCY HEMOPHILIA A Factor VIII: • Regulates the activation of factor X by proteases. • Synthesized in liver, complexed tovWF. • On the X chromosome. Coagulation Disorders
HEMOPHILIA A • Female carriers have sufficient factor VIII. • However, occasional hemophilia carriers will have factor VIII levels far below 50% due to random inactivation of normal X chromosomes in tissue producing factor VIII. • Rarely, true female hemophiliacs arise from consanguinity within families with hemophilia or from concomitant Turner's syndrome or XO mosaicism in a carrier female. Coagulation Disorders
HEMOPHILIA A • One in 5,000 males is born with deficiency or dysfunction of the factor VIII molecule (one in 10,000 in both FVIII and IX def.). Coagulation Disorders
HEMOPHILIA A • <5% FVIII: symptomatic. • <1%: severe disease. • 1-5%: moderate disease. • >5%: mild disease. Coagulation Disorders
HEMOPHILIA A • The majority of patients with hemophilia A have factor VIII levels below <5%. Coagulation Disorders
HEMOPHILIA A • Hemophilic bleeding occurs hours or days after injury. • This can result in large collections of partially clotted blood putting pressure on adjacent normal tissues. Coagulation Disorders
HEMOPHILIA A • Retroperitoneal hematoma • Large calcified masses (pseudotumor syndrome). • Cephalhematoma or profuse bleeding at circumcision • Hemarthrosis • Hematuria, usually self-limited • Oropharyngeal and central nervous system bleeding (the most feared complications of hemophilia) Coagulation Disorders
HEMOPHILIA A Laboratory Diagnosis • Typically, the patient will have a prolonged PTT with all other tests normal. • Any male with an appropriate bleeding history and a prolonged PTT should have specific assays for factor VIII and factor IX. Coagulation Disorders
HEMOPHILIA A Treatment • Avoid the use of aspirin or aspirin-containing drugs, which impair platelet function and may cause severe hemorrhage. COX-2 inhibitors can be used, as they do not impair platelet function. • Factor VIII replacement Coagulation Disorders
HEMOPHILIA A Plasma products: • Fresh frozen plasma • Cryoprecipitate (around 80U per bag) • Factor VIII concentrates Coagulation Disorders
HEMOPHILIA AManagement Calculation of FVIII replacement • 1 U of FVIII = 1 ml of normal plasma. • Normal plasma volume: 50 ml/kg of BW. • A healthy person has 50U FVIII/kg of BW • Half-life of 8 to 12 h • FVIII replacement: target level - baseline level x wt(kg) x 0.5 Coagulation Disorders
HEMOPHILIA AManagement • In patients with mild hemophilia, an alternative treatment is desmopressin (DDAVP), which transiently increases the factor VIII level. DDAVP will increase the factor level two- to threefold. Coagulation Disorders
HEMOPHILIA AManagement • Skilled orthopedic care. • Antifibrinolytic therapy: e-aminocaproic acid (EACA), and tranexamic acid. • Gene therapy Coagulation Disorders
HEMOPHILIA AComplications • Viral Hepatitis • AIDS • Factor inhibitors Coagulation Disorders
FACTOR IX DEFICIENCY Hemophilia B (Christmas disease ) • Occurs in 1 in 100,000 male births. • Indistinguishable clinically from factor VIII deficiency. • Therapy: FFP or a plasma fraction enriched in the prothrombin complex proteins. • Monoclonally purified or recombinant factor IX preparations are now available. • Replacement: target-baseline x wt(kg) x 1U/kg Coagulation Disorders
OTHER FACTOR DEFICIENCIES • Deficiencies in factors V, VII, X, and prothrombin (factor II) are exceedingly rare autosomal recessive disorders. • Therapy: FFP, Prothrombin concentrates Coagulation Disorders
OTHER FACTOR DEFICIENCIES Hageman factor (factor XII), HMWK, and PK • PTT often >100 • Normal hemostasis • No clinical bleeding. • Direct activation of factor IX by the tissue factor-VIIa complex may bypass this defective step in coagulation . Coagulation Disorders
FACTOR XIII DEFICIENCY AND DEFECTIVE FIBRIN CROSS-LINKING • Usually bleed in the neonatal period from their umbilical stump or circumcision. • Poor wound healing • A high incidence of infertility among males and abortion among affected females. • Enzyme may be important in placental implantation, spermatogenesis, and wound healing. • Drugs: Isoniazid • Normal hemostasis requires only 1% of normal enzyme activity, which can be achieved with a single infusion of fresh-frozen plasma or a purified factor XIII-rich product • Factor XIII has a 14-day half-life. Coagulation Disorders
Acquired Coagulation Disorders • More frequent and more complex • Affecting both primary and secondary hemostasis. DIC Liver disease Vitamin K deficiency Anticoagulant therapy Coagulation Disorders
VITAMIN K DEFICIENCY • Following absorption and transport, vitamin K is converted to an active epoxide in liver microsomes and serves as a cofactor in the enzymatic carboxylation of glutamic acid residues on prothrombin complex proteins. Coagulation Disorders
VITAMIN K DEFICIENCY • Inadequate dietary intake • Intestinal malabsorption • Loss of storage sites due to hepatocellular disease. • Neonatal vitamin K deficiency • Warfarin usage Coagulation Disorders
VITAMIN K DEFICIENCY • Decrease in factors II, VII, IX, X; proteins C and S. • Factor VII and protein C, which have the shortest half-lives, decrease first. Coagulation Disorders
COAGULATION DISORDERS IN LIVER DISEASE • Prolongation of the PT and PTT. • Mild thrombocytopenia. • Normal fibrinogen level. • Therapy: fresh-frozen plasma. Coagulation Disorders
CIRCULATING ANTICOAGULANTS • Circulating anticoagulants, or inhibitors, are usually IgG. • They arise in 15 to 20% of patients with factor VIII or factor IX deficiency who have received plasma infusions. • Specific inhibitors also occur in previously normal individuals. • In addition to hemophiliacs, anti-factor VIII antibodies are seen in postpartum females, in patients on various drugs, as part of the spectrum of autoantibodies in SLE patients, and in normal elderly individuals and in patients with AIDS. Coagulation Disorders